Informed Prostate Cancer Patient Support

DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy - Carignan - - The Prostate - Wiley Online Library : Background Radiotherapy and brachytherapy are common treatments for localized prostate cancer (PCa). However, very few studies evaluated the association of variations in DNA damage response genes an...

New diagnostic tools aim to catch aggressive prostate cancer early : Two newly published studies are presenting novel diagnostic techniques to help catch the most aggressive forms of prostate cancer at an early stage. A University of East Anglia study presents an innovative way to measure gene expression in tumor samples and predict disease severity, while an…

Improved Imaging for Prostate Cancer With PSMA PET-CT : A novel imaging technique was more accurate than conventional CT with bone scanning at detecting pelvic and distant metastases in high-risk prostate cancer.

'MultiD': Taking the Bias Out of Prostate Cancer Tx | MedPage Today : No, it's not a vitamin, it's a new model of care planning

Older Patients With Cancer Especially Vulnerable to Coronavirus - MedicineNet Health News : For oncologists and other clinicians caring for patients with cancer, the COVID-19 pandemic represents a dynamic clinical challenge that is changing daily and that can feel overwhelming at times, say experts.

Study: Prostate Cancer Leaves Detectable ‘Fingerprint’ in Blood | Cooking with Kathy Man : A test that can detect the genetic “fingerprint” of prostate cancer in blood could improve diagnosis, monitoring and treatment of the disease, researchers say. The test checks for prost…

Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases : The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive and prognostic biomarkers for metastatic castration-resistant prostate cancer (mCRPC). Serial plasma specimens were prospectively collected from 88 chemotherapy-naive mCRPC patients before and after 12 weeks of AA/P treatment. Sequencing-based CNA analyses were performed on 174 specimens. We evaluated CNA-associated 12-week responses for primary resistance, time to treatment change (TTTC) for secondary resistance, and overall survival for prognosis (P < 0.05). Associations with prim...